The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2024 | Tackling underrepresentation of minorities in CAR-T clinical trials for multiple myeloma
Monika Engelhardt, MD, University Medical Center Freiburg, Freiburg, Germany, comments on the issue of inadequate representation of ethnic minorities during clinical trial investigations of CAR T-cell immunotherapeutics in patients with multiple myeloma. Dr Engelhardt emphasizes the importance of ensuring diverse representation across clinical trials in different geographical regions and the necessity of equitable treatment so that all patients benefit from clinical trials’ success and the development of novel immunotherapeutic agents. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
